Journey Medical Sees Emrosi Joining Plan Covering 25 Million Lives in 2027

Journey Medical expects Emrosi to join a national plan covering more than 25 million lives in 2027, a move management expects to shift prescriptions toward reimbursed sales. Emrosi generated $9 million in third-quarter sales, with about 40,000 prescriptions and more than 5,000 unique prescribers. Emrosi currently has high-quality access for 40% of commercial lives. Journey Medical also posted positive adjusted EBITDA for a second consecutive quarter. Changes to copay bridging contributed to prescription volatility. Management said first-quarter deductible resets may affect average selling price progression. Journey Medical is weighing 2027 guidance and has expressed caution about issuing it early in the year. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.